North of England Life Science Accelerator
North of England Life Science Accelerator

About the Partners

Established by the BioCity Group, the New Venture Accelerator Programme is a collaboration between Manchester Science Partnerships, The N8 Research Partnership and the Northern Health Science Alliance together. Seed funding is available through Alderley Park Ventures and Catapult Ventures.
The programme aims to increase the creation and growth of small businesses in the life science and healthcare sectors in the North of England. The experience, connections and availability of funding through this collaboration, provides a unique opportunity to accelerate early stage businesses and academic projects exploring commercialisation.

Successful applicants will benefit from business support programmes, access to facilities, introductions to experts and funding. Support will be offered in a structured, networked and highly collaborative environment to enable you to explore the potential of your business to grow and expedite the transition to the next stage.



The BioCity Group specialises in the creation and development of life science businesses. Providing homes for businesses, access to high-end equipment, shared services, training, business support and access to investment for new and growing bioscience businesses. Over 200 companies are based in a BioCity Group business incubator, making the BioCity network one of the largest concentrations of life science businesses in the UK.
BioCity will deliver programmes which help discover scalable business models for companies, clear routes to raising investment, accelerated paths to market and coaching in the latest tools for entrepreneurial excellence. Through these programmes, companies will be introduced to experts with significant experience in diverse areas of life sciences and commercialisation, via the extensive BioCity Expert Network,

Manchester Science Partnerships

Manchester Science Partnerships (MSP) is a unique collaboration of organisations from across the private, public, academic and clinical sectors. Working closely with stakeholders and partners including The University of Manchester, Manchester Metropolitan University, Manchester City Council, Cheshire East Council, Salford City Council and the Central Manchester Hospitals NHS Foundation Trust (CMFT), Manchester Science Partnerships is a knowledge-broker connecting entrepreneurs, investors and researchers from across the science, health and technology sectors.
Manchester Science Partnerships are the owners of Alderley Park, a site with a strong history of drug discovery and development, set in 400 acres of Cheshire countryside. The park is a dedicated Life Science Enterprise Zone, offering 1m sq ft of premier scientific laboratory space and over 400,000 sq ft of office space.

Alderley Park will be the home of the North of England Life Science Accelerator, hosting the accelerator programmes and events, providing lab space and hot desks for successful businesses and access to equipment and facilities.

The N8 Research Partnership

The N8 research partnership is a collaboration of the eight most research intensive Universities in the North of England: Durham, Lancaster, Leeds, Liverpool, Manchester, Newcastle, Sheffield and York. Working with universities, industry and society, N8 aims to maximise the impact of this research base by promoting collaboration, establishing innovative research capabilities and developing programmes of national and international prominence driving economic growth.
The programme will capitalise on the rich wealth of knowledge and innovation within the North of England Universities. The N8 will play a key role in collaboration by linking academics to the programme and facilitating links between the businesses and universities other than their host institution.



The Northern Health Science Alliance delivers access on an unparalleled scale across eight research intensive universities, eight NHS teaching trusts, four Academic Health Science Networks and the North’s 15 million population. The NHSA provides one point of access to the health science system across the North of England.

The NHSA will be key to supporting your businesses requiring clinical engagement. The NHSA has rapid processes and tools for engagement from technology scouting to industry led grant applications. The alliance of 8 NHS Teaching Trusts is uniquely placed to help set up and coordinate multi-centre clinical trials alongside industrial partners. 8 top universities provide an active and responsive network of academics, clinicians and support bodies that work with companies and streamlined connections to research centres across the region. The 4 Academic Health Science Networks provide advice on establishing technology and clinical development programmes in the North and the UK.

Alderley Park Ventures

Alderley Park Ventures (APV) is a £5M incubation fund managed by the BioCity Group Ltd to support companies establishing themselves on the Alderley Park site where BioCity are partnered with MSP; forming the BioHub incubator. In addition to providing facilities and incubation support to emerging Life science companies APV also provide seed investment (£50K-250K) either off balance sheet or through our associated Investment Funds (Alderley Park Ventures and Mobius Technologies). By working closely with companies on site we feel that this can give us invaluable insight into the business & management teams and, ultimately allow us to make more successful investment decisions.

Catapult Ventures - GM&C Life Sciences Fund
Managed by Catapult Ventures, the GM&C Life Sciences Fund is a seed and early stage venture capital fund targeting life sciences businesses located in the Greater Manchester and Cheshire & Warrington region.

The Fund is the result of a collaboration between Cheshire and Warrington Local Enterprise Partnership, Greater Manchester Combined Authority, Cheshire East Council, and Manchester Science Partnerships and can be invested in ‘Life Science’ businesses across the following sectors:
• Pharmaceuticals
• Biotechnology
• Diagnostics
• Life Science contract research organisations (CRO)
• Healthcare technologies
• Medical devices

With contributions from both private and public sector partners, the size of the Fund, at launch, is around £31m. Full details can be found at:

Catapult Ventures

Catapult Ventures is an independent venture capital fund manager that has been investing in UK businesses across a range of sectors since 2002. Catapult’s owners operate a number of discrete funds on behalf of public and private sector investors with a total of c. £130m under the owners’ management. Notable realisations (over 4x return) include Blackstar Amps (4.3x), R5 Pharmaceuticals (4.7x), Whelan Refining (4.7x), QEK (4.5x), Lumora (5x), Oxford Cryosystems (5.3x), Systems Integration (4.9x) and Accutronics (9.1x). Catapult also invested in Abzena (AIM: ABZA) which listed in 2014.

Catapult Ventures and Catapult Ventures Group are trading names of Catapult Ultimate Holdings Ltd, which is the ultimate holding company of Catapult Venture Managers Ltd, which is authorised and regulated by the Financial Conduct Authority.



Frequently Asked Questions       


Contact us

For a copy of the business proposal template and further details on the application process please contact us today: